Cue Biopharma, Inc. Financial Ratios — 1UC0 Stock

Profitability (USD)

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Return on Common Equity (%)	- -	-69.27	-60.52	-81.57	-82.88	-67.1	-61.16	-80.82	-98.73	-149.03	-121.11
Return on Assets (%)	- -	-64.92	-55.83	-69.41	-62.75	-52.34	-48.28	-60.69	-66.4	-86.8	-71.51
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Gross Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EBITDA Margin (%)	- -	- -	- -	-3,320.19	-1,039.76	-1,427.96	-292.56	-4,130.04	-887.3	-421.56	-84
Operating Margin (%)	- -	- -	- -	-3,386.71	-1,063.21	-1,427.96	-292.56	-4,297.35	-947.03	-447.86	-96.56
Incremental Operating Margin (%)	- -	- -	- -	- -	83.23	2,721.44	11.29	71.48	35.57	273.87	82.91
Pretax Margin (%)	- -	- -	- -	-3,339.33	-1,049.25	-1,413.26	-292.25	-4,257.83	-924.1	-437.97	-95.03
Profit Margin (%)	- -	- -	- -	-3,411.53	-1,061.18	-1,419.79	-295.56	-4,257.83	-924.1	-437.97	-96.85
Net Income to Common Margin (%)	- -	- -	- -	-3,411.53	-1,061.18	-1,419.79	-295.56	-4,257.83	-924.1	-437.97	-96.85
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Dvd Payout Ratio (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Sustainable Growth Rate (%)	- -	-69.27	-60.52	-81.57	-82.88	-67.1	-61.16	-80.82	-98.73	-149.03	-121.11

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Total Debt	- -	- -	3	- -	6	7	10	19	15	9	4
ST Debt	- -	- -	3	- -	4	5	5	5	7	8	2
LT Debt	- -	- -	- -	- -	1	2	5	14	7	1	2
Total Debt/EBITDA	- -	- -	-0.11	- -	-0.16	-0.16	-0.23	-0.38	-0.3	-0.23	-0.18
Net Debt/EBITDA	3.4	2	2.68	0.55	1.23	1.66	1.47	0.81	0.83	0.46	1.18
Total Debt/EBIT	- -	- -	-0.11	- -	-0.16	-0.16	-0.23	-0.36	-0.28	-0.21	-0.16
Net Debt/EBIT	3.32	1.95	2.63	0.54	1.2	1.66	1.47	0.78	0.77	0.44	1.02
EBITDA to Interest Expense	- -	- -	- -	- -	- -	- -	- -	-72.12	-39.13	-49.18	-64.63
EBITDA-CapEx/Interest Expense	- -	- -	- -	- -	- -	- -	- -	-72.36	-39.13	-49.27	-65.12
EBIT to Interest Expense	- -	- -	- -	- -	- -	- -	- -	-75.04	-41.76	-52.25	-74.29
Interest Expense	- -	- -	- -	- -	- -	- -	- -	1	1	1	- -
Common Equity/Total Assets	94.86	93.22	92.01	74.89	76.23	79.28	78.53	71.95	60.27	54.36	62.62
Long-Term Debt/Equity (%)	- -	- -	- -	- -	2.47	3	7.82	21.4	19.86	5.73	8.65
Long-Term Debt/Capital (%)	- -	- -	- -	- -	2.23	2.75	6.78	16.53	14.22	3.8	7.46
Long-Term Debt/Total Assets (%)	- -	- -	- -	- -	1.88	2.38	6.14	15.39	11.97	3.12	5.42
Total Debt/Equity (%)	- -	- -	4.06	- -	10.62	9.06	15.35	29.41	39.63	50.72	15.88
Total Debt/Capital (%)	- -	- -	3.9	- -	9.6	8.3	13.31	22.73	28.38	33.65	13.7
Total Debt/Total Assets (%)	- -	- -	3.73	- -	8.09	7.18	12.05	21.16	23.88	27.57	9.94
Net Debt to Equity	-92.32	-98.36	-99.07	-61.23	-81.14	-94.87	-98.29	-63.36	-108.8	-103.58	-102.66
Net Debt/Capital (%)	-1,201.45	-5,998.64	-10,641.77	-157.92	-275.27	-668.95	-576.07	-124.66	-1,235.43	-462.87	-776.87
EBITDA	-2	-7	-23	-38	-36	-45	-44	-51	-49	-39	-23
EBITDA-CapEx	-3	-8	-24	-40	-36	-46	-45	-52	-49	-39	-23
Operating Income (Loss)	-2	-8	-23	-39	-37	-45	-44	-54	-52	-42	-27

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Accounts Receivable Turnover	- -	- -	- -	- -	9.16	2.9	6.55	0.78	6.26	7.03	8.46
Days Sales Outstanding	- -	- -	- -	- -	39.84	125.69	55.7	469.01	58.34	51.94	43.13
Inventory Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Days Inventory Outstanding	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Accounts Payable Turnover Days	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventory to Cash Days	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Inventories	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Raw Materials	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Work In Process	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Finished Goods	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Other Inventory	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Market Capitalization	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
- Cash & Cash Equivalents	6	15	64	21	44	75	64	52	49	22	27
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
+ Total Debt	- -	- -	3	- -	6	7	10	19	15	9	4
Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Capital	7	15	64	34	60	86	76	85	52	26	31
Total Debt/Capital (%)	- -	- -	3.9	- -	9.6	8.3	13.31	22.73	28.38	33.65	13.7
Total Debt / EV	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Sales	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBITDA	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/EBIT	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV/Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Market Cap	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Diluted Enterprise Value	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
EV per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
TTM Sales	- -	- -	- -	1	3	3	15	1	5	9	27
TTM EBITDA	-2	-7	-23	-38	-36	-45	-44	-51	-49	-39	-23
TTM Operating Income	-2	-8	-23	-39	-37	-45	-44	-54	-52	-42	-27
TTM Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
TTM Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

No data availableFinancial data will appear here once available

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y
As of date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025

Shares Outstanding	1	1	1	1	1	1	1	1	2	2	3
Diluted Weighted Avg Shares	1	1	1	1	1	1	1	1	2	2	3
Basic Weighted Avg Shares	1	1	1	1	1	1	1	1	2	2	3
Revenue per Share	- -	- -	- -	1.7	4.71	3.3	14.33	1.05	3.6	4.95	8.7
EBITDA per Share	-2.74	-10.84	-33.16	-56.53	-48.94	-47.1	-41.92	-43.27	-31.94	-20.85	-7.31
Operating Income per Share	-2.8	-11.13	-33.77	-57.66	-50.04	-47.1	-41.92	-45.02	-34.09	-22.15	-8.4
Basic EPS, GAAP	-2.8	-11.13	-33.77	-58.08	-49.95	-46.83	-42.35	-44.61	-33.26	-21.66	-8.42
Basic EPS from Cont Ops	-2.8	-11.13	-33.77	-58.08	-49.95	-46.83	-42.35	-44.61	-33.26	-21.66	-8.42
Diluted EPS, GAAP	-2.8	-11.13	-33.77	-58.08	-49.95	-46.83	-42.35	-44.61	-33.26	-21.66	-8.42
Diluted EPS from Cont Ops	-2.8	-11.13	-33.77	-58.08	-49.95	-46.83	-42.35	-44.61	-33.26	-21.66	-8.42
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Cash Flow per Share	-2.41	-8.67	-17.65	-39.35	-41.92	-33.98	-37.24	-35.18	-26.2	-19.35	-6.87
Free Cash Flow per Basic Share	-3.51	-9.42	-19.4	-42.12	-41.98	-34.6	-38.12	-35.33	-26.2	-19.38	-6.92
Cash & Equivalents per Share	9.38	21.77	92.34	56.84	67.1	83.89	59.97	53.17	30.83	10.9	8.43
Book Value per Share	10.08	22.06	89.54	49.24	61.65	78	61.01	45.78	23.56	8.49	8.21
Tangible Book Value per Share	10.08	22.06	89.29	49.24	61.65	78	61.01	45.78	23.56	8.49	8.21